White paper

biosimilars landscape white paper

The landscape of available biosimilars

The landscape of available biosimilars


Biosimilars have the potential to deliver significant cost savings across healthcare. Recent biosimilar approvals and launches have led to a market shift for payers, specialty providers, and their patients. These highly similar biologics offer new possibilities for increasing access to life-changing therapies, providing patients with more affordable options for treating conditions such as cancer, autoimmune diseases, and diabetes.

In this white paper, we delve into the concept of biosimilars, their distinctions from generics, their impact on reimbursement policies, and the challenges and opportunities they present to healthcare providers, payers, and manufacturers.

 

Complete the form below for instant access to the white paper today.

White paper

The Inflation Reduction Act (IRA) and its implications for intellectual property incentives to develop drugs for select populations

Webinar

The Missing PIEce: Best Practices for Implementing Pre-Approval Information Exchange (PIE) in a Payer Communication Plan

Article

Interview: Evolving and expanding global consulting with local expertise

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.